Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 1
1987 2
1988 2
1989 4
1992 2
1993 1
1994 6
1995 1
1996 3
1997 2
1998 8
1999 10
2000 5
2001 7
2002 7
2003 3
2004 4
2005 1
2006 3
2007 9
2008 5
2009 5
2010 6
2011 5
2012 7
2013 15
2014 7
2015 9
2016 10
2017 8
2018 11
2019 17
2020 20
2021 21
2022 28
2023 28
2024 32
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. Among authors: howell sj. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Free PMC article. Clinical Trial.
Reply.
Ayyash K, Howell SJ, McGinigle KL. Ayyash K, et al. Among authors: howell sj. J Vasc Surg. 2024 Apr;79(4):986-987. doi: 10.1016/j.jvs.2023.11.063. J Vasc Surg. 2024. PMID: 38519221 Free article. No abstract available.
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP; VERITAC-2 Study Group. Campone M, et al. N Engl J Med. 2025 Aug 7;393(6):556-568. doi: 10.1056/NEJMoa2505725. Epub 2025 May 31. N Engl J Med. 2025. PMID: 40454645 Clinical Trial.
Tamoxifen evolution.
Howell A, Howell SJ. Howell A, et al. Among authors: howell sj. Br J Cancer. 2023 Feb;128(3):421-425. doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10. Br J Cancer. 2023. PMID: 36765172 Free PMC article. Review. No abstract available.
Perioperative care in open aortic vascular surgery: A consensus statement by the Enhanced Recovery After Surgery (ERAS) Society and Society for Vascular Surgery.
McGinigle KL, Spangler EL, Pichel AC, Ayyash K, Arya S, Settembrini AM, Garg J, Thomas MM, Dell KE, Swiderski IJ, Lindo F, Davies MG, Setacci C, Urman RD, Howell SJ, Ljungqvist O, de Boer HD. McGinigle KL, et al. Among authors: howell sj. J Vasc Surg. 2022 Jun;75(6):1796-1820. doi: 10.1016/j.jvs.2022.01.131. Epub 2022 Feb 16. J Vasc Surg. 2022. PMID: 35181517 Free article. Review.
Just a Generator Exchange?
Howell SJ, Stecker EC. Howell SJ, et al. Circ Cardiovasc Qual Outcomes. 2023 Aug;16(8):519-520. doi: 10.1161/CIRCOUTCOMES.123.010266. Epub 2023 Jul 26. Circ Cardiovasc Qual Outcomes. 2023. PMID: 37492957 Free article. No abstract available.
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, Logan J, Twomey K, Khatun M, D'Cruz CM, Turner NC. Rugo HS, et al. Among authors: howell sj. ESMO Open. 2024 Sep;9(9):103697. doi: 10.1016/j.esmoop.2024.103697. Epub 2024 Sep 5. ESMO Open. 2024. PMID: 39241495 Free PMC article. Clinical Trial.
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group. Oliveira M, et al. Among authors: howell sj. Lancet Oncol. 2024 Sep;25(9):1231-1244. doi: 10.1016/S1470-2045(24)00373-5. Lancet Oncol. 2024. PMID: 39214106 Clinical Trial.
309 results